Anti-Fibrinolytic Drugs - Europe | Statista Market Forecast

The Anti-Fibrinolytic Drugs market in Europe is estimated to generate a revenue of US$3.11bn by the year 2024.
It is projected to experience a steady annual growth rate (CAGR 2024-2029) of 4.61%, leading to a market volume of US$3.89bn by 2029.
When compared globally, United States is expected to generate the highest revenue, reaching US$9.86bn in 2024.
In Europe, Germany is leading the way in the adoption of anti-fibrinolytic drugs, with a strong emphasis on research and development.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

Anti-Fibrinolytic Drugs, also known as antifibrinolytics, are medications that help control bleeding by preventing blood clots from breaking down too quickly. These drugs are used in a variety of medical procedures and conditions, such as surgery, trauma, and bleeding disorders. In Europe, the market for Anti-Fibrinolytic Drugs has been showing some interesting trends and developments.

Customer preferences: The increasing demand for Anti-Fibrinolytic Drugs in Europe is driven by the rising incidence of bleeding disorders and the growing number of surgeries being performed. Patients and healthcare providers are also becoming more aware of the benefits of these drugs in controlling bleeding and reducing the need for blood transfusions.

Trends in the market: In recent years, the market for Anti-Fibrinolytic Drugs in Europe has been growing steadily. This growth is expected to continue in the coming years, driven by the increasing use of these drugs in surgical procedures and the rising prevalence of bleeding disorders. The market is also seeing the emergence of new drugs and formulations, which are expected to further drive growth.

Local special circumstances: The market for Anti-Fibrinolytic Drugs in Europe is characterized by a high degree of competition, with several major players competing for market share. The market is also subject to strict regulations, which can affect the availability and pricing of these drugs. Additionally, there are significant differences in the use of these drugs across different countries and regions in Europe, which can impact market dynamics.

Underlying macroeconomic factors: The growth of the Anti-Fibrinolytic Drugs market in Europe is being driven by several underlying macroeconomic factors. These include the aging population, which is leading to an increase in the number of surgeries and the prevalence of bleeding disorders. Additionally, the increasing healthcare expenditure and the growing demand for cost-effective treatments are driving the adoption of Anti-Fibrinolytic Drugs in Europe.In conclusion, the market for Anti-Fibrinolytic Drugs in Europe is showing steady growth, driven by the increasing demand for these drugs in surgical procedures and the rising prevalence of bleeding disorders. The market is also seeing the emergence of new drugs and formulations, which are expected to further drive growth. However, the market is subject to strict regulations and significant differences in the use of these drugs across different countries and regions in Europe, which can impact market dynamics.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.